

Debra A Howell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5994817/publications.pdf>

Version: 2024-02-01

41
papers

1,156
citations

471061

17
h-index

395343

33
g-index

43
all docs

43
docs citations

43
times ranked

1471
citing authors

#	ARTICLE	IF	CITATIONS
1	Cohort Profile Update: The Haematological Malignancy Research Network (HMRN) UK population-based cohorts. <i>International Journal of Epidemiology</i> , 2022, 51, e87-e94.	0.9	7
2	Incurable but treatable: Understanding, uncertainty and impact in chronic blood cancers – A qualitative study from the UK’s Haematological Malignancy Research Network. <i>PLoS ONE</i> , 2022, 17, e0263672.	1.1	17
3	Treatment decision making (TDM): a qualitative study exploring the perspectives of patients with chronic haematological cancers. <i>BMJ Open</i> , 2022, 12, e050816.	0.8	9
4	Excess morbidity and mortality among survivors of childhood acute lymphoblastic leukaemia: 25 years of follow-up from the United Kingdom Childhood Cancer Study (UKCCS) population-based matched cohort. <i>BMJ Open</i> , 2022, 12, e056216.	0.8	4
5	Preferred and actual place of death in haematological malignancies: a report from the UK haematological malignancy research network. <i>BMJ Supportive and Palliative Care</i> , 2021, 11, 7-16.	0.8	19
6	Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. <i>BMJ Open</i> , 2021, 11, e041296.	0.8	5
7	P-010: An economic model to establish the costs associated with routes of presentation for patients with Myeloma in the UK. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S44.	0.2	0
8	“Unpacking” pathways to lymphoma and myeloma diagnosis: Do experiences align with the Model of Pathways to Treatment? Findings from a UK qualitative study with patients and relatives. <i>BMJ Open</i> , 2020, 10, e034244.	0.8	12
9	Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study. <i>Palliative Medicine</i> , 2019, 33, 518-530.	1.3	32
10	Disease-related factors affecting timely lymphoma diagnosis: a qualitative study exploring patient experiences. <i>British Journal of General Practice</i> , 2019, 69, e134-e145.	0.7	15
11	Haematology nurses' perspectives of their patients' places of care and death: A UK qualitative interview study. <i>European Journal of Oncology Nursing</i> , 2019, 39, 70-80.	0.9	17
12	Hodgkin lymphoma detection and survival: findings from the Haematological Malignancy Research Network. <i>BJGP Open</i> , 2019, 3, bjgpopen19X101668.	0.9	8
13	Change in Physiological Variables in the Last Two Weeks of Life: An Observational Study of Hospitalized Adults With Heart Failure. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 1335-1340.	0.6	3
14	Palliative care specialists’ perceptions concerning referral of haematology patients to their services: findings from a qualitative study. <i>BMC Palliative Care</i> , 2018, 17, 33.	0.8	49
15	Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK’s Haematological Malignancy Research Network (HMRN). <i>British Journal of Haematology</i> , 2018, 181, 215-228.	1.2	36
16	Determinants of hospital death in haematological cancers: findings from a qualitative study. <i>BMJ Supportive and Palliative Care</i> , 2018, 8, 78-86.	0.8	39
17	Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. <i>International Journal of Epidemiology</i> , 2018, 47, 700-700g.	0.9	47
18	Myeloma: Patient accounts of their pathways to diagnosis. <i>PLoS ONE</i> , 2018, 13, e0194788.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. <i>British Journal of Haematology</i> , 2017, 177, 67-71.	1.2	39
20	Emergency admission and survival from aggressive non-Hodgkin lymphoma: A report from the UK's population-based Haematological Malignancy Research Network. <i>European Journal of Cancer</i> , 2017, 78, 53-60.	1.3	22
21	Factors associated with hospital death in patients with haematological malignancies: findings from a UK population-based study. <i>BMJ Supportive and Palliative Care</i> , 2016, 6, 395.2-395.	0.8	0
22	Why do patients with haematological malignancies die in hospital? Qualitative findings from a UK study. <i>BMJ Supportive and Palliative Care</i> , 2016, 6, 395.1-395.	0.8	0
23	Mantle Cell Lymphoma Management and Outcome in the U.K.'s Population-Based Haematological Malignancy Research Network. <i>Blood</i> , 2016, 128, 1112-1112.	0.6	8
24	Novel Targeted Therapies and Their Impact on Survival from Multiple Myeloma (MM) and Chronic Lymphocytic Leukaemia (CLL) in the Real World. <i>Blood</i> , 2016, 128, 3546-3546.	0.6	0
25	Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. <i>Cancer Epidemiology</i> , 2015, 39, 1103-1112.	0.8	45
26	Caring for terminal patients in haematology: the urgent need of a new research agenda. <i>Supportive Care in Cancer</i> , 2015, 23, 5-7.	1.0	14
27	Risk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma. <i>British Journal of Cancer</i> , 2015, 113, 1114-1120.	2.9	19
28	Change in physiological variables in the last 2 weeks of life: An observational study of hospital in-patients with cancer. <i>Palliative Medicine</i> , 2015, 29, 120-127.	1.3	14
29	Community palliative care clinical nurse specialists: a descriptive study of nurse-patient interactions. <i>International Journal of Palliative Nursing</i> , 2014, 20, 246-253.	0.2	10
30	Long-Term Medical Costs and Life Expectancy of Acute Myeloid Leukemia: A Probabilistic Decision Model. <i>Value in Health</i> , 2014, 17, 205-214.	0.1	18
31	Place of death in haematological malignancy: variations by disease sub-type and time from diagnosis to death. <i>BMC Palliative Care</i> , 2013, 12, 42.	0.8	34
32	Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network. <i>BMC Blood Disorders</i> , 2013, 13, 9.	0.9	94
33	Skeletal-Related Events In Myeloma: A Population-Based Study. <i>Blood</i> , 2013, 122, 3158-3158.	0.6	5
34	Social Inequality Is An Important Risk Factor For Death From Chronic Myeloid Leukaemia: Findings From a UK Population-Based Cohort. <i>Blood</i> , 2013, 122, 4036-4036.	0.6	0
35	Illness patterns prior to diagnosis of lymphoma: Analysis of UK medical records. <i>Cancer Epidemiology</i> , 2011, 35, 145-150.	0.8	3
36	Non-Hodgkin lymphoma and autoimmunity: Does gender matter?. <i>International Journal of Cancer</i> , 2011, 129, 460-466.	2.3	36

#	ARTICLE	IF	CITATIONS
37	Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. <i>Palliative Medicine</i> , 2011, 25, 630-641.	1.3	191
38	Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. <i>BMC Palliative Care</i> , 2010, 9, 9.	0.8	93
39	The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. <i>British Journal of Haematology</i> , 2010, 148, 739-753.	1.2	126
40	What determines referral of UK patients with haematological malignancies to palliative care services? An exploratory study using hospital records. <i>Palliative Medicine</i> , 2007, 21, 487-492.	1.3	33
41	On The Emergence of Complex Disasters. <i>Disasters</i> , 1997, 21, 177-180.	1.1	7